Key result
Echocardiographic structural heart disease affects ~15% of adults with HIV on ART.
Why the study?
Improved survival on antiretroviral therapy has shifted morbidity in HIV infection towards non-communicable cardiac disease, yet echocardiographic data on structural heart disease prevalence and its associations from South Asia remain sparse.
Cross-Sectional (n=126)
No
Approximately one in seven adults with HIV on antiretroviral therapy in eastern Nepal had unsuspected structural heart disease (primarily dilated cardiomyopathy and valvular disease) independent of age, sex, or CD4 count, supporting routine echocardiographic screening in this population.
Answers are grounded in this paper and cite their sources.
Indicates notable cardiac burden in treated HIV; leaves open whether routine echocardiography improves outcomes in this setting.
Background: Improved survival on antiretroviral therapy has shifted morbidity in human immunodeficiency virus infection towards non-communicable cardiac disease, yet echocardiographic data from South Asia remain sparse. Aims/Objectives: To determine the prevalence of structural heart disease, comprising dilated cardiomyopathy and valvular heart disease, and its association with age, sex and CD4 count. Methodology: A hospital-based cross-sectional study enrolled 126 consecutive adults on antiretroviral therapy at a tertiary centre in eastern Nepal between August 2018 and July 2019. Those with hypertension, alcohol dependence, cardiotoxic drug exposure or pre-existing cardiac or systemic disease were excluded. All underwent transthoracic echocardiography and CD4 estimation. Results: Structural heart disease was present in 19 (15.1%) participants: dilated cardiomyopathy in 14 (11.1%) and valvular heart disease in 7 (5.6%). Prevalence did not differ across age groups (χ² = 0.94, p = 0.627) or by sex (11/64 men, 17.2%, versus 8/62 women, 12.9%; odds ratio 1.40, 95% CI 0.52–3.76, p = 0.502). Mean CD4 count was similar in affected and unaffected participants (627 ± 309 versus 551 ± 248 cells/µL; t = 1.18, p = 0.239). Conclusions: One in seven treated adults had unsuspected structural heart disease, independent of age, sex and CD4 count, supporting routine echocardiographic screening.
No takes yet. Share an insight, caveat, or question.
Mishra et al. (2026) conducted a cross-sectional in Human immunodeficiency virus (HIV) infection on antiretroviral therapy (n=126). HIV infection on antiretroviral therapy (evaluated by transthoracic echocardiography) was evaluated on Prevalence of structural heart disease (comprising dilated cardiomyopathy and valvular heart disease) (OR 1.40, 95% CI 0.52-3.76, p=0.502). Adults with HIV on antiretroviral therapy had a 15.1% prevalence of echocardiographic structural heart disease, independent of age, sex, and CD4 count.
Synapse has enriched 10 related papers. Consider them for comparative context: